Noticias y Actividades de Ironwood Pharmaceuticals

Ironwood Pharmaceuticals es una de las ...

• Russell 3000;
• TOB Iconic 10,000.

Ironwood Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización IRWD (US).

Fusión, adquisición y financiación con participación de Ironwood Pharmaceuticals.

• Ironwood Pharmaceuticals has announced the acquisition of VectivBio  (publicado el 25 de mayo de 2023).

Ver el organigrama con sus 20 ejecutivos principales

Biografías más buscadas en Ironwood Pharmaceuticals

• Thomas McCourt, Chief Executive Officer and Director
• Catherine Moukheibir, Director
• Julie McHugh, Chairman of the Board

Recientes movimientos de ejecutivos en Ironwood Pharmaceuticals

• Tammi Gaskins que ha sido Vice President of Brand Management, ha ascendido a Senior Vice President and Chief Commercial Officer  (noticia publicada el 30 de enero de 2025).
• Sravan Emany, Senior Vice President, Chief Financial Officer and Chief Operations Officer, ha dejado la empresa  (noticia publicada el 30 de diciembre de 2024).

Crear su alerta
para seguir los movimientos de los ejecutivos en Ironwood Pharmaceuticals.

Ironwood Pharmaceuticals tiene 1.833 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Eli Lilly (Estados Unidos).

Popular M&A news in Farmacia

• Imbria Pharmaceuticals acaba de anunciar una recaudación de fondos de 58 millones de dólares. (publicado el 10 de abril de 2025).
• Clario ha NRx Pharmaceuticals adquirido (publicado el 18 de marzo de 2025).
• Knight Therapeutics has announced the acquisition of Paladin Labs  (publicado el 12 de marzo de 2025).

Otros contactos sugeridos en el sector Farmacia

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets en Bristol-Myers Squibb
• Kristin Berkinsky - Chief Human Resources Officer en Adare Pharmaceuticals
• Paul Meister - Chairman of the Board en Amneal Pharmaceuticals

Saber más sobre el sector Farmacia

Últimos comunicados de prensa de Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing
• Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance
• Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call
• Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future
• Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference
• Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference
• Ironwood Pharmaceuticals Reports Third Quarter 2024 Results
• Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024
• Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call
• Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
• View more press releases Close

Redes sociales sobre Ironwood Pharmaceuticals

• Ironwood Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
• Ironwood Pharmaceuticals en LinkedIn, Twitter y YouTube